The psychological and physiological effects of MDMA on normal volunteers

The paper situates MDMA within the family of methylenedioxy-substituted phenylisopropylamines, noting its distinction from classic mescaline-like hallucinogens by producing sensory amplification and affective openness rather than pronounced perceptual distortion. Earlier preclinical toxicology and reviews are described as indicating a relatively large safety margin for therapeutic oral doses compared with animal LD50s, and prior human reports—most notably by Shulgin—have characterised MDMA as producing an ‘‘affective interaction’’ useful in psychotherapy at doses commonly cited as 75–150 mg. This study sets out to characterise the psychological and physiological effects of MDMA in normal volunteers. The investigators aimed to document neurobehavioural changes, autonomic and motor effects, and standard blood chemistry measures across the acute and subacute time course after ingestion, in order to inform safety and practical recommendations for clinical or research use.

The extracted text does not present a formally labelled Methods section with full procedural details such as randomisation, dose, route of administration, or inclusion/exclusion criteria. However, the account indicates that a group of volunteers was given MDMA and assessed at several time points: pre-ingestion, one to two hours post-ingestion, four to five hours post-ingestion, and approximately 24 hours post-ingestion for some participants. Different assessments were completed by varying numbers of participants for different measures. Neurobehavioural and neurological examinations included measures of short-term memory, digit repetition, simple arithmetic (multiplication), judgment tasks, alertness and lucidity, pupil size and light reflex, nystagmus, jaw clench and jaw reflex, deep tendon reflexes, finger-to-nose testing, gait and coordination, and sleep and appetite reports. Physiological monitoring included heart rate and blood pressure measurements (with reporting of baseline, peak, six-hour and 24-hour values for subsets of subjects), and electrocardiograms in a small subgroup. Biochemical evaluation comprised serial blood chemistry panels (thyroid, renal, serum amylase, creatine phosphokinase, glucose, electrolytes, albumin, albumin/globulin ratio), with 11 subjects providing three panels, six providing two panels, and four providing a single panel. The study team did not describe a formal statistical analysis plan in the extracted text; where sample sizes for specific measures were small or variable, the authors describe the data as suggestive rather than definitive.

Across the sample, subjects reported heightened sensual awareness, increased physical and emotional energy, and feelings of euphoria without evidence of confused thinking. No visual or auditory hallucinations were observed. Sexual arousal increased for some participants and a rise in frequency of sexual contact within 24 hours was reported by a subset. Appetite was suppressed in almost all individuals for the 24-hour period; two subjects reported increased sleep quantity, and one subject experienced nausea and vomiting at about three hours. Headache and insomnia were absent in the reported sample. Neurobehavioural testing showed no change in short-term memory or digit repetition from baseline. Difficulty with multiplication occurred in three of 10 subjects at peak drug levels, and judgment was impaired in four of 10 subjects at one to two hours post-ingestion, implying that complex decision-making may be affected during the acute phase. Tests of coordination were affected: gait instability or incoordination was observed in seven subjects, finger-to-nose testing was impaired in two subjects at one to two hours, and deep tendon reflexes were enhanced in eight of 10 subjects with a return to baseline by four to five hours. Jaw clench was evident in six of 10 subjects and diminished by four hours, persisting mildly in one subject at 24 hours. Autonomic and cardiovascular observations included pupillary dilation in all subjects except one who was blind, with intact light reflex. Nystagmus was present in eight subjects at one to two hours and largely resolved by four hours; equivocal nystagmus persisted at 24 hours in two subjects. An illustrative individual case showed pulse rising from 72 beats per minute to 148 within 30 minutes and to 128 at two hours. By six hours, 60% (nine of 14) of those measured had blood pressures below predose levels, and among 12 subjects with 24-hour blood pressure data, five were below their pre-ingestion pressures but still within normal limits. Electrocardiograms were reported as normal in the five subjects tested. Blood chemistry results revealed no clear, consistent abnormalities: thyroid, renal, serum amylase and creatine phosphokinase tests were within normal ranges. Blood glucose was elevated in six samples, but the investigators noted lack of control over food and drink limits interpretation. Mild elevations above laboratory maxima were seen sporadically for potassium, calcium and phosphorus, and albumin was elevated in seven samples; an increased albumin/globulin ratio appeared in nine samples, several of which were present before drug testing. The authors characterised the biochemical data as not showing any striking or statistically significant abnormalities, emphasising that variable sampling reduced definitiveness.

Braun and colleagues interpret the findings as consistent with prior characterisations of MDMA producing sensory amplification, increased sociability and affective openness without the perceptual distortions typical of classic hallucinogens. Acute subjective effects included euphoria and heightened sensual awareness, and objective testing indicated transient impairments in coordination and some aspects of judgment and motor control during the peak drug period. In terms of safety, the authors note no major biochemical derangements and normal electrocardiograms in the small subgroup tested, but they caution that animal toxicology findings and human therapeutic dosing are judged in context: therapeutic oral doses are a small fraction of animal LD50s, yet individual physiological responses varied. Practical recommendations drawn from the data include postponing important decision-making and avoiding tasks requiring significant coordination while under the acute influence of MDMA. The investigators also emphasise that some measured effects—particularly blood chemistry findings—are suggestive rather than definitive because of variable sampling frequency and lack of controls for factors such as food and fluid intake. Limitations acknowledged in the extracted text include small and inconsistent sample sizes across different measures (for example, only five participants had ECGs, and blood chemistry panels varied in number per participant), absence of controlled dietary conditions, and the lack of detailed methodological description in the extracted material. The authors position their results as informing safety and practical precautions for MDMA use in supervised contexts and as consistent with prior reports of the compound's distinct psychoactive profile, while recognising the need for more systematic data to draw firmer conclusions.